Dr. Leland Gershell
Recent Articles
Biopharma Shares Efficacy Data at AUA Meeting 05/01/2025
These results and input from key opinion leaders boost "our enthusiasm for this candidate's prospects as a treatment for non-muscle, invasive bladder cancer, noted an Oppenheimer report.
Analyst's Target Price for Biotech Massively Higher Than Current Price 07/22/2024
Oppenheimer & Co. recently put out a report that gave NuCana Plc. (NCNA:NASDAQ) a target price of US$150. The stock is currently trading at US$2.98. Read on to see why the analyst has given the company such a massive target price.
Approval Likely in U.S., EU for New Drug for Prader-Willi 10/12/2023
Despite recent positive clinical trials, the biopharma behind this treatment remains undervalued presenting a buying opportunity, noted an Oppenheimer report.
Due to permission requirements, not all quotes are shown.
